Cleveland Clinic Study Is First to Show Success in Treating Rare Blood Disorder
September 19, 2024
September 19, 2024
CLEVELAND, Ohio, Sept. 19 (TNSres) -- The Cleveland Clinic issued the following news release:
* * *
Trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to successful findings
* * *
A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide. The t . . .
* * *
Trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to successful findings
* * *
A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide. The t . . .